Bhuiamla Extract
Also known as: Bhuiamla, Bhui Amla, Stonebreaker, Phyllanthus amarus Schumach. & Thonn., Phyllanthus amarus
Overview
Bhuiamla extract is derived from *Phyllanthus amarus*, a small herb traditionally used in Ayurvedic and Unani medicine. It is recognized for its hepatoprotective, antiviral, antioxidant, and antidiabetic properties. The extract contains bioactive compounds such as phyllanthin, hypophyllanthin, flavonoids, and lignans, which are believed to be responsible for its therapeutic effects. While numerous preclinical studies support its potential benefits, high-quality randomized controlled trials (RCTs) in humans are limited, indicating a moderate level of research maturity. The evidence base largely consists of in vitro and animal model studies, with fewer robust human clinical trials available to establish definitive clinical efficacy and safety.
Benefits
Bhuiamla extract exhibits several evidence-based benefits, primarily in preclinical settings. Its **hepatoprotective effects** are well-documented in in vitro and in vivo studies, showing protection against various liver toxins (e.g., alcohol, carbon tetrachloride) by reducing oxidative stress and improving liver enzyme profiles. This benefit is supported by multiple studies, though human clinical significance needs further establishment. The extract also demonstrates **antiviral activity** against hepatitis B virus (HBV) DNA polymerase and other viruses like HIV, dengue, and herpes simplex in vitro, suggesting potential as an antiviral agent. Furthermore, animal studies indicate **antidiabetic effects**, including reduced blood glucose levels and improved liver glucokinase activity, pointing to its role in glucose metabolism. Lastly, Bhuiamla acts as an **antioxidant and anti-inflammatory agent** by scavenging free radicals and modulating inflammatory pathways. While these benefits are promising, most evidence comes from preclinical research, and robust human clinical trials are needed to confirm efficacy and determine optimal use in humans.
How it works
Bhuiamla's therapeutic actions are attributed to its rich phytochemical composition. Its hepatoprotective effects are primarily mediated through its potent antioxidant activity, which involves scavenging reactive oxygen species and preserving hepatic glutathione levels, thereby protecting liver cells from damage. The extract also modulates key inflammatory pathways, such as NF-κB, TNF-α, and IL-6/STAT-3 signaling, contributing to its anti-inflammatory properties. The antiviral mechanisms include inhibition of viral DNA polymerase and interference with early stages of viral replication. Bioactive compounds like phyllanthin are thought to play a significant role in these effects. However, specific details regarding its absorption, bioavailability, and precise interaction with human body systems are not yet fully elucidated.
Side effects
Bhuiamla extract is generally considered safe based on traditional use and animal studies, with no major toxicity reported at typical doses. However, comprehensive long-term safety data in humans are scarce, making it difficult to fully assess its safety profile for prolonged use. There are no commonly documented serious side effects in the reviewed literature. Due to its potential polyherbal composition in some preparations, interactions with conventional drugs are a theoretical concern and warrant caution. Specific contraindications for use, as well as safety data for special populations such as pregnant or breastfeeding women, children, or individuals with pre-existing medical conditions, are insufficiently studied. Therefore, while generally well-tolerated, further research is needed to establish its complete safety profile and potential drug interactions.
Dosage
There is currently no standardized or clinically established dosing regimen for Bhuiamla extract due to the lack of high-quality human clinical trials. Animal studies typically utilize oral doses of 200–400 mg/kg body weight of the extract; however, these dosages do not directly translate to human equivalent doses and should not be used as a guide for human consumption. The efficacy and bioavailability of the extract may vary significantly depending on the formulation (e.g., aqueous vs. ethanolic extracts) and timing of administration. Information regarding cofactors or absorption enhancers that might improve its effectiveness is also not well-studied. Without robust human clinical data, specific recommendations for dosage, timing, or upper safety limits cannot be provided. Individuals considering Bhuiamla should consult a healthcare professional for guidance.
FAQs
Is Bhuiamla extract effective for liver diseases?
Preclinical evidence strongly supports its hepatoprotective effects, but robust human clinical trials are still needed to confirm its efficacy in treating liver diseases in humans.
Is Bhuiamla extract safe for long-term use?
While traditional use suggests safety, comprehensive long-term human safety data are currently lacking, so caution is advised for extended use.
Can Bhuiamla extract be used with antiviral drugs?
Potential interactions with conventional drugs exist, especially given its polyherbal nature. Consultation with a healthcare provider is strongly recommended before combining it with antiviral medications.
How soon might benefits appear from Bhuiamla extract?
Animal studies show effects after weeks of administration, but human data are insufficient to determine how quickly benefits might manifest in people.
Research Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7132358/ – This study investigated the hepatoprotective activity of a proprietary extract (BV-7310) containing *P. amarus*. It demonstrated antioxidant, anti-inflammatory, and hepatoprotective effects in vitro and in vivo through modulation of pathways like PPARγ and NF-κB, though it lacked human data.
- https://ijsra.net/sites/default/files/IJSRA-2022-0302.pdf – This review summarized the phytochemical and pharmacological potential of *P. amarus*, reporting its antiviral activity against HBV, HIV, and dengue, as well as antidiabetic effects in diabetic rats. The findings are primarily based on preclinical studies, with no randomized controlled trials.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9660160/ – This review provided insights into the medicinal properties of *P. amarus*, highlighting its broad pharmacological activities including hepatoprotection, antioxidant, and antiviral effects. It detailed mechanisms involving glutathione preservation and radical scavenging, noting the limited clinical trial data.
- https://www.ijpsjournal.com/article/AntiInflammatory+and+Cardiovascular+Benefits+of+Phyllanthus+Niruri+A+Phytotherapeutic+Perspective+ – This review, focusing on the related species *Phyllanthus niruri*, discussed challenges in clinical translation and safety concerns for *Phyllanthus* species. It emphasized the need for more rigorous toxicity studies and high-quality human trials to establish efficacy and safety.
